NCT01808768

Ocular Allergy Treatment Practical Impact Trial

To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Starx Research Center, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.

Detailed description

To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)

Conditions

• Allergic Conjunctivitis
• Rhinoconjunctivitis

Interventions

Type	Name	Description
DRUG	Alcaftadine	Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.

Timeline

• Start date: 2013-04-01
• Primary completion: 2013-10-01
• Completion: 2013-11-01
• First posted: 2013-03-11
• Last updated: 2013-05-30

Locations

2 sites across 1 country: United States